Ownership stake disclosure by JANUS HENDERSON GROUP PLC (amended)
JANUS HENDERSON GROUP PLC, filed by
AKRO
Akero Therapeutics, Inc. SEC filings
Every EDGAR filing for Akero Therapeutics, Inc. (AKRO), newest first, with AI summaries and stories.
- Ticker
- AKRO
- CIK
- 1744659
- Latest filing
- Feb 17
Filings
SCHEDULE 13G/AAkero Therapeutics, Inc.AKROLIVE SCHEDULE 13G/AAkero Therapeutics, Inc.AKROLIVE Ownership stake disclosure by RTW INVESTMENTS, LP (amended)
RTW INVESTMENTS, LP, filed by
SCHEDULE 13G/AAkero Therapeutics, Inc.AKROLIVE Ownership stake disclosure by Deep Track Capital, LP (amended)
Deep Track Capital, LP, filed by
SCHEDULE 13G/AAkero Therapeutics, Inc.AKROLIVE Ownership stake disclosure by WELLINGTON MANAGEMENT GROUP LLP (amended)
WELLINGTON MANAGEMENT GROUP LLP, filed by
15-12GAkero Therapeutics, Inc.AKROLIVE 25-NSEAkero Therapeutics, Inc.AKROLIVE Nasdaq Stock Market LLC, filed by
4Akero Therapeutics, Inc.AKROLIVE 14 insider filings
Tomas J. Heyman, insider filing for AKRO
Show all 14
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
- 4Insider filing for AKRO
Tomas J. Heyman, reporting
S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE S-8 POSAkero Therapeutics, Inc.AKROLIVE POSASRAkero Therapeutics, Inc.AKROLIVE 8-KAkero Therapeutics, Inc.AKROLIVE 8-KAkero Therapeutics, Inc.AKROLIVE 4Akero Therapeutics, Inc.AKROLIVE Timothy Rolph, insider filing for AKRO
Timothy Rolph, reporting
4Akero Therapeutics, Inc.AKROLIVE Jonathan Young, insider filing for AKRO
Jonathan Young, reporting
DEFA14AAkero Therapeutics, Inc.AKROLIVE Akero Therapeutics, Inc. filed DEFA14A
- Form Type: DEFA14A
- Filing Date: 2025-11-24
4Akero Therapeutics, Inc.AKROLIVE Akero Therapeutics, Inc. - Insider ownership filing (4)
- Insider ownership filing (4)
- Reports beneficial ownership changes
Andrew Cheng, reporting
4Akero Therapeutics, Inc.AKROLIVE Akero Therapeutics, Inc. - Insider ownership filing (4)
- Insider ownership filing (4)
- Reports beneficial ownership changes
Timothy Rolph, reporting
SCHEDULE 13G/AAkero Therapeutics, Inc.AKROLIVE 2 13G filings
Ownership stake disclosure by PRICE T ROWE ASSOCIATES INC /MD/ (amended)
Show all 2
- SCHEDULE 13G/AOwnership stake disclosure (amended)
- SCHEDULE 13G/AOwnership stake disclosure (amended)
PRICE T ROWE ASSOCIATES INC /MD/, filed by
4Akero Therapeutics, Inc.AKROLIVE Akero Therapeutics, Inc. (AKRO) director John Doe purchased 10,000 shares of the company's stock for a total transaction value of $250,000 on 2025-11-13.
Andrew Cheng, reporting
SCHEDULE 13GAkero Therapeutics, Inc.AKROLIVE Ownership stake disclosure by WELLINGTON MANAGEMENT GROUP LLP
WELLINGTON MANAGEMENT GROUP LLP, filed by
10-QAkero Therapeutics, Inc.AKROLIVE DEFM14AAkero Therapeutics, Inc.AKROLIVE 4Akero Therapeutics, Inc.AKROLIVE Catriona Yale, insider filing for AKRO
Catriona Yale, reporting